Unlocking The Potential of BNIPL: A Unique Protein with A Potential Drug Target Or Biomarker

Target Name: BNIPL

NCBI ID: G149428

BNIPL

Unlocking The Potential of BNIPL: A Unique Protein with A Potential Drug Target Or Biomarker

BNIPL (Bcl2 interacting protein like, transcript variant 2) is a protein that is expressed in various tissues throughout the body. It is a member of the Bcl2 gene family, which is known for its role in regulating cell death and survival. BNIPL is a unique protein that has been identified as a potential drug target or biomarker due to its unique structure and function.

The Bcl2 gene family consists of four proteins: Bcl2, Bcl21, Bcl22, and Bcl23. All of these proteins are characterized by a shared domain that includes a conserved structural feature: a 21 amino acid residue that is often referred to as the Bcl2 signature . This signature is located at the N-terminus of each protein and is responsible for the formation of a distinct N-terminal region that is unique to each protein.

BNIPL is a 21 amino acid protein that is expressed in various tissues throughout the body. It is highly conserved in its structure, with a similar overall folding pattern as the other Bcl2 proteins. However, BNIPL has a unique feature that sets it apart from the other Bcl2 proteins. Specifically, BNIPL has a 10 amino acid insertion at its C-terminus. This insertion results in a longer N-terminus region for BNIPL, which is unique among the Bcl2 proteins.

The function of BNIPL is not well understood, but its unique structure and conserved features suggest that it plays an important role in cell survival and stress response. BNIPL has been shown to be involved in a variety of cellular processes, including cell survival, cell cycle regulation, and DNA damage repair.

One of the potential reasons why BNIPL is a drug target or biomarker is its unique structure and function. The Bcl2 protein family has been shown to play a role in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The unique structure and function of BNIPL make it an attractive target for researchers to investigate and develop new drugs or biomarkers.

In addition to its potential as a drug target or biomarker, BNIPL also has the potential to serve as a therapeutic agent for a variety of diseases. For example, BNIPL has been shown to be involved in the regulation of cell death and has been shown to protect against chemotherapy-induced cell death in cancer cells. Additionally, BNIPL has been shown to play a role in the regulation of cell cycle progression and has been shown to inhibit the effects of radiation on cancer cells.

In conclusion, BNIPL is a unique protein that has been identified as a potential drug target or biomarker due to its unique structure and function. The Bcl2 gene family has been shown to play a role in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The unique structure and function of BNIPL make it an attractive target for researchers to investigate and develop new drugs or biomarkers. Additionally, BNIPL has the potential to serve as a therapeutic agent for a variety of diseases. Further research is needed to fully understand the role of BNIPL in cell biology and to develop new treatments for a variety of diseases.

Protein Name: BCL2 Interacting Protein Like

Functions: May be a bridge molecule between BCL2 and ARHGAP1/CDC42 in promoting cell death

The "BNIPL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BNIPL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets